Skip to content
Medical Health Aged Care

7 Stars, A New Glory of Yangtze in Global Quality Management

Yangtze River Pharmaceutical Group 2 mins read

TAIZHOU, China, Oct. 30, 2025 (GLOBE NEWSWIRE) -- On the evening of October 16th (European Standard Time), at the EFQM Sustainable Performance Conference and Global Award Gala 2025 held in Spain, Yangtze River Pharmaceutical Group (hereinafter ‘Yangtze’) received the “7 stars” Certificate in the category of RbE on-site review. As a new breakthrough in the field of quality management after the winning of “5 Diamonds” at the “EFQM Global Award” in 2021, the “7 Stars” award marks that the quality management level of Chinese pharmaceutical enterprises has reached a new height in the world.

7 Stars, A New Glory of Yangtze in Global Quality Management

“This is not the end, but rather a new starting point in our continuous pursuit of excellence,” said by an executive from Yangtze. According to the interview, the escalation from 5 to 7 Stars certification achieved in a span of four years is attributed to Yangtze’s continuous promotion and internalization of the “Mode of Excellent Performance” and the “EFQM Model”. In April this year, after a 5-day review by the panel of experts from Germany, UK, Portugal, etc., a rigorous “physical examination” comprising 30 interviews and 450 Q&As regarding this enterprise’s strategic execution, innovation mechanism, operational performance, brand building and cultural blending, a consensus was reached for recognizing its advanced strength.

7 Stars, A New Glory of Yangtze in Global Quality Management

The review process brought the experts into a journey of witnessing Yangtze’s innovative localized integration of the EFQM model, especially the iterated development of the course “EFQM Blooming at Yangtze”, transforming international standards into internal management language and action guideline. Yangtze Group is now using the universal “management language” in summarizing and presenting their work performance, which is an advanced concept for motivating all-staff actions.

Industry experts believe that Yangtze’s winning of this year’s award not only highlights the strength of Chinese pharmaceutical brands in the international field of quality management, in a more practical sense, this path of “international standards benchmarking - localized transformation - full-scale implementation” provided a sample for Chinese enterprises in adapting to international standards and achieving high-quality development.

Company: Yangtze River Pharmaceutical Group

Contact Person: Yang wen

Email: [email protected]

Website: https://en.yangzijiang.com/

Telephone: 0086 4009881999

City: Taizhou

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/5231d230-a653-44ec-857f-b7a30e0140f7

https://www.globenewswire.com/NewsRoom/AttachmentNg/aebc04b0-6c7e-48dd-88bc-f0a3f01d0f33


More from this category

  • Medical Health Aged Care
  • 22/01/2026
  • 23:11
Concept Medical Inc.

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first…

  • Contains:
  • Medical Health Aged Care
  • 22/01/2026
  • 22:11
Sinovac Biotech Ltd.

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and…

  • Medical Health Aged Care
  • 22/01/2026
  • 17:11
Galderma

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.